Skip to main content
. 2018 May 1;2(3):429–438. doi: 10.1002/rth2.12102

Figure 2.

Figure 2

(A) Risk of recurrent VTE in 6 months in randomized controlled trials of DOAC vs LMWH (random effect model).48 (B) Risk of major bleeding in 6 months in randomized controlled trials of DOAC vs LMWH (random effect model).48 CI, confidence interval; DOAC, direct oral anticoagulants; LMWH, low‐molecular‐weight heparin; M‐H, Mantel‐Haenszel; VTE, venous thromboembolism